A Study to Select the Dose and Evaluate the Effectiveness and Safety of the Drug Refralon®, Tablets, 1 mg for Long-term Use to Prevent Recurrence of Atrial Fibrillation/Flutter After Terminating Its Persistent Form

A phase 2 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 175 participants.

Also called NCT06540352

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 175 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT06540352
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Russia (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT06540352. Randomized; quadruple masking; primary purpose treatment. Start 2024-06-03 (actual); primary completion 2026-12-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study to Select the Dose and Evaluate the Effectiveness and Safety of the Drug Refralon®, Tablets, 1 mg for Long-term Use to Prevent Recurrence of Atrial Fibrillation/Flutter After Terminating Its Persistent Form
Intervention (Drug)
4-Nitro-N-[(1RS)-1-(4-fluorophenyl)-2-(1-ethylpiperidin-4-yl)ethyl]benzamide hydrochloride
Intervention (Drug)
Mannitol
Lead sponsor
National Medical Research Center for Cardiology, Ministry of Health of Russian Federation (class: other government)

Record details

Record id
cardio:ct-nct06540352
Content hash
9d6316978836e5a68718a9184ab2028ccfcd95ce5d35df3840ced5fe889e2ddc